MedPath

Effects of Black Tea Intake on Serum Lipids

Not Applicable
Completed
Conditions
Hypercholesterolemia
Interventions
Dietary Supplement: Tea Treatment Group
Dietary Supplement: Placebo
Registration Number
NCT01882283
Lead Sponsor
University of Minnesota
Brief Summary

A diet-controlled clinical trial which attempts to provide estimates of the effect of black tea consumption on serum lipids under tightly controlled conditions, including a controlled diet. Mildly hypercholesterolemic individuals (total cholesterol levels between 4.9 and 6.7 mmol/L, 190 and 260 mg/dl), non-smoking, chronic disease-free individuals were enrolled in a 15-week, double blind, randomized crossover trial, during which they consumed a controlled low-flavonoid diet plus 5 cups of black tea or a tea-like placebo over two 4-week treatment periods.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
57
Inclusion Criteria
  • between 45-65 years old
  • mildly hypercholesterolemic (total cholesterol levels between 4.9 and 6.7 mmol/L, 190 and 260 mg/dl)
  • high-density lipoprotein cholesterol (HDL-C) between 0.9 and 1.6 mmol/L (35 and 65 mg/dl)
  • triglyceride (TG) concentrations below 6.8 mmol/L (600 mg/dl)
  • habitually consumed a typical American diet with low dietary flavonoid intake (<4 one-half cup servings of fruits and vegetables/day) and low intake (<1 serving/day) of soy-rich foods, nuts, herbs, and spices (besides salt and pepper)
  • aspartate aminotransferase (AST) between 0 and 55 mg/L
  • creatinine between 70.7 and 150.3 mmol/L (0.8 and 1.7 mg/dl)
  • glucose between 3.3 and 6.4 mmol/L (60 and 115 mg/dl)
Read More
Exclusion Criteria
  • current smoker
  • usage of high amounts of antioxidant vitamin supplements (>3 times the Recommended Dietary Allowance (RDA) of vitamins E, C, and selenium, or >10 mg/day of beta carotene)
  • had been diagnosed with diabetes, coagulation disorders, chronic pulmonary disease, current active malignancy, renal disease requiring dialysis, malabsorption, or gastrointestinal disorders, or had a history of cardiovascular disease.
  • antihypertensive, immunosuppressive, cholesterol lowering, or anticoagulant medications
  • consuming >3 servings of alcohol daily
  • Pre-menopausal (women)
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Tea Treatment GroupTea Treatment Group5 cups brewed tea beverage per day for 28 days, brewed from 700 mg of black tea solids per cup
Placebo GroupPlacebo5 cups tea-like placebo per day for 28 days. Placebo was exactly matched to tea except for flavonoid composition. Placebo was flavonoid-free.
Primary Outcome Measures
NameTimeMethod
Serum lipid levels4 weeks

Serum lipid levels (total cholesterol, LDL-C, HDL-C, triglycerides, LDL-C+HDL-C fraction, LDL-C/HDL-C ratio) were assessed at the end of a 28-day treatment period

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

General Clinical Research Center, University of Minnesota

🇺🇸

Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath